US$3.65-per-share cash deal would take Quipt (QIPT) private under Kingswood
Quipt Home Medical Corp. has called a special shareholder meeting to approve an arrangement under which a Kingswood-affiliated buyer will acquire all outstanding Quipt shares for US$3.65 in cash per share.
The March 3, 2026 meeting will ask investors to pass a special resolution requiring at least two‑thirds of votes cast, plus a separate simple majority excluding certain related holders under MI 61‑101. If approved and court‑sanctioned, Quipt will go private, its shares will be delisted, and options and RSUs will be cashed out. A termination fee of $6.95 million may be payable in specified failure or superior‑proposal scenarios.
Positive
- All-cash exit at defined price: Shareholders are offered US$3.65 in cash per Quipt share, giving immediate liquidity and valuation certainty upon closing of the arrangement, with options and RSUs similarly cashed out.
Negative
- Deal and go-private risk: Completion depends on multiple approvals and conditions, including supermajority and minority shareholder votes, court orders, and regulatory clearances; if the transaction fails, Quipt remains public without the cash payout.
Insights
Quipt seeks shareholder and court approval for a US$3.65-per-share cash go‑private transaction backed by Kingswood.
The proposed arrangement would see a Kingswood‑controlled vehicle acquire all Quipt shares for
Closing depends on multiple conditions, including the “Required Quipt Approval” (two‑thirds of votes cast plus a majority excluding related parties), court orders from the Supreme Court of British Columbia, and regulatory clearances; the
SECURITIES AND EXCHANGE COMMISSION
Securities Exchange Act of 1934
Wilder, Kentucky 41076
| | | THE BOARD OF DIRECTORS OF QUIPT UNANIMOUSLY RECOMMENDS THAT QUIPT SHAREHOLDERS VOTE “FOR” THE ARRANGEMENT RESOLUTION. | | |
Chief Executive Officer
| |
|
| |
North American Toll Free Phone: 1-800-530-5189
Local and text: 416-751-2066
Email: info@carsonproxy.com
|
|
Wilder, Kentucky 41076
To Be Held On March 3, 2026
Chief Executive Officer
January 23, 2026
| |
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
|
| | | | 1 | | |
| |
SUMMARY OF THE MATERIAL TERMS OF THE ARRANGEMENT
|
| | | | 5 | | |
| |
The Arrangement and the Arrangement Agreement
|
| | | | 15 | | |
| |
The Quipt Meeting
|
| | | | 18 | | |
| |
Record Date and Quorum
|
| | | | 18 | | |
| |
Other Important Considerations
|
| | | | 19 | | |
| |
QUESTIONS AND ANSWERS ABOUT THE QUIPT MEETING AND THE ARRANGEMENT
|
| | | | 23 | | |
| |
THE ARRANGEMENT
|
| | | | 29 | | |
| |
Background to the Transaction
|
| | | | 29 | | |
| |
Reasons for the Arrangement; Recommendation of the Board
|
| | | | 36 | | |
| |
Opinions of Financial Advisors
|
| | | | 39 | | |
| |
Management Projections
|
| | | | 47 | | |
| |
Certain Effects of the Arrangement
|
| | | | 49 | | |
| |
Effects on the Company if the Arrangement is Not Completed
|
| | | | 50 | | |
| |
Delisting and Deregistration of Quipt Shares
|
| | | | 51 | | |
| |
Court Approval of the Arrangement and Completion of the Arrangement
|
| | | | 51 | | |
| |
Canadian Securities Law Matters
|
| | | | 51 | | |
| |
Minority Approval Requirements
|
| | | | 55 | | |
| |
Regulatory Approvals
|
| | | | 55 | | |
| |
Financing of the Arrangement
|
| | | | 56 | | |
| |
Guarantee
|
| | | | 57 | | |
| |
Interests of the Company’s Directors and Executive Officers in the Arrangement
|
| | | | 57 | | |
| |
Material U.S. Federal Income Tax Consequences
|
| | | | 62 | | |
| |
Material Canadian Federal Income Tax Consequences
|
| | | | 64 | | |
| |
Certain Relationships Between Purchaser and Quipt
|
| | | | 68 | | |
| |
THE PARTIES TO THE ARRANGEMENT
|
| | | | 69 | | |
| |
Quipt
|
| | | | 69 | | |
| |
Purchaser
|
| | | | 69 | | |
| |
THE QUIPT MEETING
|
| | | | 70 | | |
| |
Date, Time and Place of the Quipt Meeting
|
| | | | 70 | | |
| |
Proposals to be Considered at the Quipt Meeting
|
| | | | 70 | | |
| |
Record Date
|
| | | | 70 | | |
| |
Voting Rights; Quorum; Vote Required for Approval
|
| | | | 70 | | |
| |
Voting and Revocation of Proxies
|
| | | | 71 | | |
| |
Rights of Shareholders Who Object to the Arrangement
|
| | | | 71 | | |
| |
Solicitation of Proxies
|
| | | | 72 | | |
| |
Appointment of Proxyholder
|
| | | | 72 | | |
| |
Beneficial Ownership, NOBOs, and OBOs
|
| | | | 73 | | |
| |
Instructing your Proxyholder and Exercise of Discretion by your Proxyholder
|
| | | | 75 | | |
| |
Other Business
|
| | | | 75 | | |
| |
Questions and Additional Information
|
| | | | 75 | | |
| |
Availability of Documents
|
| | | | 76 | | |
| |
THE ARRANGEMENT AGREEMENT
|
| | | | 77 | | |
| |
Explanatory Note Regarding the Arrangement Agreement
|
| | | | 77 | | |
| |
Arrangement
|
| | | | 77 | | |
| |
Arrangement Consideration
|
| | | | 77 | | |
| |
Treatment of Options and Other Awards
|
| | | | 78 | | |
| |
Payment for the Shares
|
| | | | 78 | | |
| |
Representations and Warranties
|
| | | | 80 | | |
| |
Conduct of Business Pending the Arrangement
|
| | | | 82 | | |
| |
Efforts to Complete the Arrangement
|
| | | | 86 | | |
| |
Conditions to the Arrangement
|
| | | | 86 | | |
| |
Restrictions on Solicitations of Other Offers
|
| | | | 87 | | |
| |
Recommendation Withdrawal/Termination in Connection with a Superior Proposal
|
| | | | 90 | | |
| |
Termination of the Arrangement Agreement
|
| | | | 92 | | |
| |
Termination Fees
|
| | | | 93 | | |
| |
Employee Benefits
|
| | | | 95 | | |
| |
Indemnification and Insurance
|
| | | | 95 | | |
| |
Amendment, Extension and Waiver
|
| | | | 96 | | |
| |
Specific Performance
|
| | | | 96 | | |
| |
Governing Law
|
| | | | 97 | | |
| |
DISSENTING SHAREHOLDERS’ RIGHTS
|
| | | | 98 | | |
| |
MARKET PRICE OF QUIPT SHARES
|
| | | | 101 | | |
| |
RISK FACTORS
|
| | | | 103 | | |
| |
DIVIDENDS
|
| | | | 106 | | |
| |
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
|
| | | | 107 | | |
| |
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
|
| | | | 109 | | |
| |
OTHER MATTERS
|
| | | | 110 | | |
| |
Other Matters for Action at the Quipt Meeting
|
| | | | 110 | | |
| |
Future Shareholder Proposals
|
| | | | 110 | | |
| |
Householding of Quipt Meeting Materials
|
| | | | 111 | | |
| |
INTERESTS OF INFORMED PERSONS IN MATERIAL TRANSACTIONS
|
| | | | 112 | | |
| |
WHERE YOU CAN FIND MORE INFORMATION
|
| | | | 113 | | |
| |
APPROVAL OF PROXY STATEMENT BY DIRECTORS
|
| | | | 114 | | |
| |
ANNEX A
ARRANGEMENT RESOLUTION
|
| | | | A-1 | | |
| |
ANNEX B
PLAN OF ARRANGEMENT
|
| | | | B-1 | | |
| |
ANNEX C
OPINION OF TRUIST SECURITIES, INC.
|
| | | | C-1 | | |
| |
ANNEX D
OPINION OF EVANS & EVANS, INC.
|
| | | | D-1 | | |
| |
ANNEX E
SECTIONS 237 TO 247 OF THE BUSINESS CORPORATIONS ACT (BRITISH COLUMBIA)
|
| | | | E-1 | | |
| |
ANNEX F
INTERIM ORDER
|
| | | | F-1 | | |
| |
ANNEX G
NOTICE OF HEARING OF PETITION FOR FINAL ORDER
|
| | | | G-1 | | |
| |
ANNEX H
PETITION AND FINAL ORDER
|
| | | | H-1 | | |
| | | |
December 14, 2025
|
| |||||||||||||||
|
Trading Price
|
| |
Minimum
|
| |
Average
|
| |
Maximum
|
| |||||||||
|
10-Days Preceding
|
| | | $ | 2.39 | | | | | $ | 2.48 | | | | | $ | 2.61 | | |
|
30-Days Preceding
|
| | | $ | 2.19 | | | | | $ | 2.38 | | | | | $ | 2.61 | | |
|
90-Days Preceding
|
| | | $ | 1.98 | | | | | $ | 2.47 | | | | | $ | 2.74 | | |
|
180-Days Preceding
|
| | | $ | 1.40 | | | | | $ | 2.23 | | | | | $ | 2.74 | | |
| | | |
Enterprise Value /
2026E Adjusted EBITDA |
| |
Enterprise Value /
2026E Adjusted EBITDA Less Capital Expenditures |
| ||||||
|
Mean
|
| | | | 4.8x | | | | | | 12.1x | | |
|
Median
|
| | | | 4.6x | | | | | | 12.1x | | |
|
Low
|
| | | | 4.3x | | | | | | 10.4x | | |
|
High
|
| | | | 5.4x | | | | | | 13.7x | | |
| | | |
FY2026
|
| |
FY2027
|
| |
FY2028
|
| |
FY2029
|
| |
FY2030
|
| |||||||||||||||
|
Net Revenue
|
| | | $ | 329.2 | | | | | $ | 335.8 | | | | | $ | 349.2 | | | | | $ | 363.2 | | | | | $ | 377.7 | | |
|
Adjusted EBITDA(1)
|
| | | $ | 67.5 | | | | | $ | 71.0 | | | | | $ | 74.6 | | | | | $ | 78.4 | | | | | $ | 82.3 | | |
|
Patient Capex
|
| | | | 51.3 | | | | | | 52.3 | | | | | | 54.3 | | | | | | 56.4 | | | | | | 58.6 | | |
|
Name, Title
|
| |
Quipt Shares
|
| |
Quipt Options(2)
|
| |
Quipt RSUs
|
| |
Percentage of Quipt
Shares, on a partially diluted, as-converted to Quipt Shares basis (%)(1) |
| ||||||||||||
|
Gregory Crawford (Chief Executive Officer & Director)
|
| | | | 3,630,778 | | | | | | 75,000 | | | | | | 959,750 | | | | | | 10.28% | | |
|
Hardik Mehta (Chief Financial Officer)
|
| | | | 884,199 | | | | | | 60,000 | | | | | | 366,471 | | | | | | 2.93% | | |
|
Mark Greenberg (Director)
|
| | | | 293,690 | | | | | | 488,750 | | | | | | 234,629(3) | | | | | | 2.26% | | |
|
Brian Wessel (Director)
|
| | | | 98,875 | | | | | | 75,000 | | | | | | 197,260(3) | | | | | | 0.83% | | |
|
Kevin Carter (Director)
|
| | | | 92,500 | | | | | | 5,625 | | | | | | 185,392(3) | | | | | | 0.64% | | |
|
Thomas William Roehrig (Chief Accounting Officer)
|
| | | | 55,125 | | | | | | 130,000 | | | | | | 117,875 | | | | | | 0.68% | | |
|
David Alan Bachelder (Executive VP of Operations)
|
| | | | 2,156 | | | | | | 80,000 | | | | | | 20,000 | | | | | | 0.23% | | |
|
Patrick Dennis Gamble (Executive VP of Operations)
|
| | | | 40,057 | | | | | | 15,000 | | | | | | 20,000 | | | | | | 0.17% | | |
|
Mark Alan Miles (Chief Compliance Officer)
|
| | | | — | | | | | | 57,500 | | | | | | 110,000 | | | | | | 0.38% | | |
|
Name, Title
|
| |
Approximate Value of
Potential Benefits ($) |
| |||
|
Gregory Crawford (Chief Executive Officer & Director)
|
| | | | 2,759,222(1)(3) | | |
|
Hardik Mehta (Chief Financial Officer)
|
| | | | 2,019,335(2)(3) | | |
|
Mark Greenberg (Director)
|
| | | | 240,046(4) | | |
|
Brian Wessel (Director)
|
| | | | 207,853(5) | | |
|
Kevin Carter (Director)
|
| | | | 198,355(6) | | |
|
Thomas William Roehrig (Chief Accounting Officer)
|
| | | | 358,875(7)(3) | | |
|
David Alan Bachelder (Executive VP of Operations)
|
| | | | 54,750(8) | | |
|
Patrick Dennis Gamble (Executive VP of Operations)
|
| | | | 54,750(9) | | |
|
Mark Alan Miles (Chief Compliance Officer)
|
| | | | 301,125(10) | | |
| TOTAL | | | | | 6,194,311 | | |
|
Name, Title
|
| |
Quipt Shares
Excluded from Voting |
| |||
|
Gregory Crawford (Chief Executive Officer & Director)
|
| | | | 3,630,778 | | |
|
Hardik Mehta (Chief Financial Officer)
|
| | | | 884,199 | | |
|
Mark Greenberg (Director)
|
| | | | 293,690 | | |
| | | |
Aggregate Amount Payable
for Quipt Shares Subject to Unvested Quipt Options |
| |
Aggregate Amount
Payable for Quipt Shares Underlying Unvested Quipt RSUs |
| ||||||
| | | |
($)(1)
|
| |
($)(2)
|
| ||||||
| Executive Officers and Directors | | | | | | | | | | | | | |
|
Non-Employee Directors(3)
|
| | | | Nil | | | | | $ | 646,254(5) | | |
|
All Other Executive Officers as a Group(4)
|
| | | | Nil | | | | | $ | 711,750 | | |
| | Date: | | | March 3, 2026 | |
| | Time: | | | 10:00 a.m. (ET) | |
| | Place: | | | Hampton Inn & Suites — Sarasota Bradenton Airport, 975 University Pkwy., Sarasota, Florida 34243 | |
|
Nasdaq
|
| |
High Trading Price
|
| |
Low Trading Price
|
| |
Volume
|
| |||||||||
|
November 2024
|
| | | $ | 2.81 | | | | | $ | 2.34 | | | | | | 2,883,605 | | |
|
December 2024
|
| | | $ | 3.16 | | | | | $ | 2.30 | | | | | | 6,113,687 | | |
|
January 2025
|
| | | $ | 3.27 | | | | | $ | 2.80 | | | | | | 3,103,756 | | |
|
February 2025
|
| | | $ | 3.20 | | | | | $ | 2.52 | | | | | | 2,690,832 | | |
|
March 2025
|
| | | $ | 2.63 | | | | | $ | 2.23 | | | | | | 2,776,686 | | |
|
April 2025
|
| | | $ | 2.34 | | | | | $ | 1.86 | | | | | | 2,756,996 | | |
|
May 2025
|
| | | $ | 2.25 | | | | | $ | 1.35 | | | | | | 47,829,765 | | |
|
June 2025
|
| | | $ | 2.21 | | | | | $ | 1.69 | | | | | | 13,881,068 | | |
|
July 2025
|
| | | $ | 2.34 | | | | | $ | 1.72 | | | | | | 610,1377 | | |
|
August 2025
|
| | | $ | 2.75 | | | | | $ | 1.90 | | | | | | 16,566,982 | | |
|
September 2025
|
| | | $ | 2.76 | | | | | $ | 2.44 | | | | | | 6,831,710 | | |
|
October 2025
|
| | | $ | 2.72 | | | | | $ | 2.32 | | | | | | 8,681,519 | | |
|
November 2025
|
| | | $ | 2.49 | | | | | $ | 2.15 | | | | | | 3,891,141 | | |
|
December 2025
|
| | | $ | 3.54 | | | | | $ | 2.35 | | | | | | 23,440,407 | | |
|
January 2026 (through January 22, 2026)
|
| | | $ | 3.61 | | | | | $ | 3.53 | | | | | | 9,309,124 | | |
|
TSX
|
| |
High Trading Price
|
| |
Low Trading Price
|
| |
Volume
|
| |||||||||
|
November 2024
|
| | | C$ | 3.92 | | | | | C$ | 3.28 | | | | | | 514,626 | | |
|
December 2024
|
| | | C$ | 4.50 | | | | | C$ | 3.32 | | | | | | 897,868 | | |
|
January 2025
|
| | | C$ | 4.75 | | | | | C$ | 4.03 | | | | | | 400,156 | | |
|
February 2025
|
| | | C$ | 4.71 | | | | | C$ | 3.56 | | | | | | 354,827 | | |
|
March 2025
|
| | | C$ | 3.78 | | | | | C$ | 3.20 | | | | | | 237,848 | | |
|
April 2025
|
| | | C$ | 3.29 | | | | | C$ | 2.68 | | | | | | 337,188 | | |
|
May 2025
|
| | | C$ | 3.11 | | | | | C$ | 1.90 | | | | | | 1,245,405 | | |
|
June 2025
|
| | | C$ | 3.01 | | | | | C$ | 2.33 | | | | | | 756,302 | | |
|
July 2025
|
| | | C$ | 3.20 | | | | | C$ | 2.36 | | | | | | 682,395 | | |
|
August 2025
|
| | | C$ | 3.80 | | | | | C$ | 2.64 | | | | | | 894,745 | | |
|
September 2025
|
| | | C$ | 3.80 | | | | | C$ | 3.40 | | | | | | 434,959 | | |
|
October 2025
|
| | | C$ | 3.79 | | | | | C$ | 3.25 | | | | | | 435,049 | | |
|
November 2025
|
| | | C$ | 3.48 | | | | | C$ | 3.04 | | | | | | 304,517 | | |
|
December 2025
|
| | | C$ | 4.87 | | | | | C$ | 3.28 | | | | | | 1,573,363 | | |
|
January 2026 (through January 22, 2026)
|
| | | C$ | 5.00 | | | | | C$ | 4.84 | | | | | | 581,272 | | |
|
Name of Beneficial Owner
|
| |
Amount and Nature of
Beneficial Ownership(1) |
| |
Percent of Quipt
Shares Outstanding(2) |
| ||||||
| Named Executive Officers | | | | | | | | | | | | | |
|
Gregory Crawford
|
| | | | 4,080,528(3) | | | | | | 9.1% | | |
|
Hardik Mehta
|
| | | | 1,096,078(4) | | | | | | 2.5% | | |
|
Thomas Roehrig
|
| | | | 231,750(5) | | | | | | * | | |
| Non-Employee Directors | | | | | | | | | | | | | |
|
Mark Greenberg
|
| | | | 884,879(6) | | | | | | 2.0% | | |
|
Kevin Carter
|
| | | | 174,287(7) | | | | | | * | | |
|
Brian Wessel
|
| | | | 256,675(8) | | | | | | * | | |
|
All directors and executive officers as a group (9 persons)
|
| | | | 6,970,160 | | | | | | 15.1% | | |
| 5% Shareholders | | | | | | | | | | | | | |
|
Forager Fund, L.P.
2025 3rd Avenue North, Suite 350
Birmingham, AL 35203
|
| | | | 4,199,562(9) | | | | | | 9.5% | | |
|
Claret Asset Management Corporation
900 de Maisonneuve O., Suite 1900
Montreal, Quebec, Canada H3A 0A8
|
| | | | 4,470,799(10) | | | | | | 10.1% | | |
|
Lakeview Opportunity Fund LLC
444 W Lake St., Suite 1900
Chicago, IL 60606
|
| | | | 3,465,178(11) | | | | | | 7.8% | | |
|
Glazer Capital, LLC
250 West 55th Street, Suite 30A
New York, New York 10019
|
| | | | 2,476,409(12) | | | | | | 5.6% | | |
|
(# of Shares)
|
| |
Edward
Kissel |
| |
Robert
MacArthur |
| |
Forager Capital
Management, LLC |
| |||||||||
|
Sole voting power
|
| | | | — | | | | | | — | | | | | | 4,199,562 | | |
|
Shared voting power
|
| | | | 4,199,562 | | | | | | 4,199,562 | | | | | | — | | |
|
Sole investment power
|
| | | | — | | | | | | — | | | | | | 4,199,562 | | |
|
Shared investment power
|
| | | | 4,199,562 | | | | | | 4,199,562 | | | | | | — | | |
|
(# of Shares)
|
| |
Lakeview
Opportunity Fund, LLC |
| |
Lakeview
Opportunity Fund GP, LLC |
| |
LIG Fund
Management, LLC |
| |
Ari B. Levy
|
| ||||||||||||
|
Sole voting power
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
|
Shared voting power
|
| | | | 3,465,178 | | | | | | 3,465,178 | | | | | | 3,465,178 | | | | | | 3,465,178 | | |
|
Sole investment power
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
|
Shared investment power
|
| | | | 3,465,178 | | | | | | 3,465,178 | | | | | | 3,465,178 | | | | | | 3,465,178 | | |
|
(# of Shares)
|
| |
Glazer
Capital, LLC |
| |
Paul J. Glazer
|
| ||||||
|
Sole voting power
|
| | | | — | | | | | | — | | |
|
Shared voting power
|
| | | | 2,476,409 | | | | | | 2,476,409 | | |
|
Sole investment power
|
| | | | — | | | | | | — | | |
|
Shared investment power
|
| | | | 2,476,409 | | | | | | 2,476,409 | | |
1019 Town Drive
Wilder, Kentucky 41076
Attention: Corporate Secretary
|
Quipt Filing
|
| |
Period/Date of Filing
|
|
| Annual Report on Form 10-K | | | Year ended September 30, 2025, filed as of December 15, 2025 | |
| Current Reports on Form 8-K | | | Filed as of December 15, 2025 (solely with respect to Item 1.01) and January 6, 2026 | |
| | | | | BY ORDER OF THE BOARD OF DIRECTORS | | |||
| | | | | By: | | |
/s/ Gregory Crawford
|
|
| | | | | | | | Name: Gregory Crawford | |
| | | | | | | | Title: Chief Executive Officer | |
INTERPRETATION
ARRANGEMENT AGREEMENT; EFFECTIVENESS
THE ARRANGEMENT
RIGHTS OF DISSENT
DELIVERY OF CONSIDERATION
AMENDMENT
WITHHOLDING TAX
PARAMOUNTCY
RELEASES
FURTHER ASSURANCES
Quipt Home Medical Corp.
1019 Town Dr.
Wilder, KY 41076
| |
SUITE 130, 3RD FLOOR, BENTALL II,
555 BURRARD STREET VANCOUVER, BRITISH COLUMBIA CANADA V7X 1M8
December 14, 2025
|
| |
19TH FLOOR, 700 2ND STREET SW
CALGARY, ALBERTA CANADA T2P 2W2 |
| |
357 BAY STREET
TORONTO, ONTARIO CANADA M5H 4A6 |
|
Wilder, Kentucky, 41076
| | | |
Unaudited
|
| |
Audited
|
| ||||||||||||||||||||||||
| | | |
For the fiscal years ending September 30,
|
| |||||||||||||||||||||||||||
|
(Expressed in ‘000s of US Dollars)
|
| |
2025
|
| |
2024
|
| |
2023
|
| |
2022
|
| |
2021
|
| |||||||||||||||
|
Cash and Cash Equivalents
|
| | | | 12,916 | | | | | | 16,174 | | | | | | 17,209 | | | | | | 8,516 | | | | | | 34,612 | | |
|
Working Capital
|
| | | | 4,525 | | | | | | 12,204 | | | | | | 4,859 | | | | | | (204) | | | | | | 24,496 | | |
|
Current Ratio
|
| | | | 1.06x | | | | | | 1.20x | | | | | | 1.08x | | | | | | 1.00x | | | | | | 1.75x | | |
|
Long Term Debt to Equity Ratio
|
| | | | 0.74x | | | | | | 0.12x | | | | | | 0.13x | | | | | | 0.09x | | | | | | 0.09x | | |
|
Total Debt to Equity
|
| | | | 0.88x | | | | | | 0.75x | | | | | | 0.72x | | | | | | 0.27x | | | | | | 0.37x | | |
| | | |
December 14, 2025
|
| |||||||||||||||
|
Trading Price
|
| |
Minimum
|
| |
Average
|
| |
Maximum
|
| |||||||||
|
10-Days Preceding
|
| | | $ | 2.39 | | | | | $ | 2.48 | | | | | $ | 2.61 | | |
|
30-Days Preceding
|
| | | $ | 2.19 | | | | | $ | 2.38 | | | | | $ | 2.61 | | |
|
90-Days Preceding
|
| | | $ | 1.98 | | | | | $ | 2.47 | | | | | $ | 2.74 | | |
|
180-Days Preceding
|
| | | $ | 1.40 | | | | | $ | 2.23 | | | | | $ | 2.74 | | |
| | | |
December 14, 2025
|
| |||||||||||||||||||||||||||
|
Trading Volume
|
| |
Minimum
|
| |
Average
|
| |
Maximum
|
| |
Total
|
| |
%
|
| |||||||||||||||
|
10-Days Preceding
|
| | | | 57,430 | | | | | | 141,400 | | | | | | 213,460 | | | | | | 1,414,000 | | | | | | 3.2% | | |
|
30-Days Preceding
|
| | | | 57,430 | | | | | | 182,936 | | | | | | 458,860 | | | | | | 5,305,130 | | | | | | 12.0% | | |
|
90-Days Preceding
|
| | | | 57,430 | | | | | | 405,607 | | | | | | 9,142,730 | | | | | | 35,693,440 | | | | | | 81.1% | | |
|
180-Days Preceding
|
| | | | 48,180 | | | | | | 617,206 | | | | | | 29,806,900 | | | | | | 107,393,790 | | | | | | 243.9% | | |
|
Consideration Premium to VWAP
|
| |
TSX — US$
|
| |
Nasdaq
US$ |
| ||||||
|
Quipt 10 - day VWAP
|
| | | $ | 2.501 | | | | | $ | 2.472 | | |
|
Implied Premium (Discount)
|
| | | | 45.9% | | | | | | 47.7% | | |
|
Quipt 20 - day VWAP
|
| | | $ | 2.402 | | | | | $ | 2.360 | | |
|
Implied Premium (Discount)
|
| | | | 51.9% | | | | | | 54.6% | | |
|
Quipt 30 - day VWAP
|
| | | $ | 2.394 | | | | | $ | 2.354 | | |
|
Implied Premium (Discount)
|
| | | | 52.4% | | | | | | 55.1% | | |
| | | |
AdaptHealth Corp.
|
| |
Owens &
Minor, Inc. |
| |
Viemed Healthcare, Inc.
|
|
|
Exchange: Ticker
|
| |
NASDAQCM: AHCO
|
| |
NYSE:OMI
|
| |
NASDAQCM: VMD
|
|
|
Market Capitalization
|
| |
1,257.3
|
| |
192.5
|
| |
264.6
|
|
|
Enterprise Value
|
| |
2,982.5
|
| |
2,274.9
|
| |
276.5
|
|
|
TTM Revenue
|
| |
3,255.2
|
| |
10,768.9
|
| |
254.8
|
|
|
CFY Revenue
|
| |
3,231.1
|
| |
3,094.1
|
| |
272.1
|
|
|
TTM EBITDA
|
| |
632.5
|
| |
506.6
|
| |
46.7
|
|
|
CFY EBITDA
|
| |
646.3
|
| |
382.2
|
| |
60.7
|
|
|
EV/ TTM Revenue
|
| |
0.92 x
|
| |
0.21 x
|
| |
1.09 x
|
|
|
EV / CFY Revenue
|
| |
0.92 x
|
| |
0.74 x
|
| |
1.02 x
|
|
|
EV / TTM EBITDA
|
| |
4.72 x
|
| |
4.49 x
|
| |
5.92 x
|
|
|
EV / CFY EBITDA
|
| |
4.61 x
|
| |
5.95 x
|
| |
4.56 x
|
|
(British Columbia)
Vancouver Registry
ACT, S.B.C. 2002, c. 57, AS AMENDED
QUIPT HOME MEDICAL CORP., THE SHAREHOLDERS OF QUIPT HOME
MEDICAL CORP., AND 1567208 B.C. LTD.
(Final Order)
| |
BEFORE
|
| |
|
| |
THE HONOURABLE JUSTICE
|
| |
|
| |
March 5, 2026
|
|
☐ party
☒ Lawyer for the petitioner
Vancouver Registry
BUSINESS CORPORATIONS ACT,
S.B.C. 2002, c. 57, AS AMENDED
INVOLVING QUIPT HOME MEDICAL CORP. THE
SHAREHOLDERS OF QUIPT HOME MEDICAL CORP.,
AND 1567208 B.C. LTD.
(FINAL ORDER)
Barristers & Solicitors
Suite 2700
1133 Melville Street
Vancouver, BC V6E 4E5
Fax No. 604.687.1612